1. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Issue 12 (December 2022) Authors: Del Mastro, Lucia; Poggio, Francesca; Blondeaux, Eva; De Placido, Sabino; Giuliano, Mario; Forestieri, Valeria; De Laurentiis, Michelino; Gravina, Adriano; Bisagni, Giancarlo; Rimanti, Anita; Turletti, Anna; Nisticò, Cecilia; Vaccaro, Angela; Cognetti, Francesco; Fabi, Alessandra; Gasparro, Simon... Journal: Lancet oncology Issue: Volume 23:Issue 12(2022) Page Start: 1571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial. (30th June 2022) Authors: Marrocco, C; Conte, B; Rossi, G; Pirrone, C; Favero, D; Massarotti, C; Anserini, P; Fregatti, P; Cardinali, B; Buzzati, G; Levaggi, A; Poggio, F; Blondeaux, E; Del Mastro, L; Lambertini, M Journal: Human reproduction Issue: Volume 37(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗